ANIP vs HQY: fair value comparison
ANI Pharmaceuticals, Inc. and HealthEquity, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ANIP currently sits closer to the top of our ranking by discount to fair value.
| ANIP | HQY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $72.29 | $92.03 |
| 12-month range | $70.16–$94.48 | $73.21–$106.79 |
| Rank by discount to fair value | #7 of 108 Healthcare | #10 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Undervalued | — |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: ANIP fair value analysis · HQY fair value analysis